Is pazopanib/pazopanib included in the scope of medical insurance reimbursement?

Pazopanib As an innovative targeted anti-cancer drug, Pazopanib has been widely used around the world in recent years and has been approved for marketing in China. In terms of medical insurance, the original brand name of pazopanib is VOTRIENT, which has been included in China’s national basic medical insurance drug catalog and has become one of the targeted tumor treatment drugs within the scope of medical insurance reimbursement. According to the latest medical insurance policy, Vitant is mainly suitable for the treatment of advanced renal cell carcinoma, especially first-line treatment, or for patients who have previously received cytokine therapy but whose disease has not been effectively controlled.

In other words, only patients who are diagnosed with advanced renal cancer and meet the medical insurance indications can enjoy part or most of the drug reimbursement according to national and local medical insurance policies. In addition, medical insurance may also have certain restrictions on the dosage and treatment time of pazopanib. The attending physician is required to indicate the necessity of treatment when issuing a prescription, and the relevant medical insurance approval mechanism will conduct verification.

For other non-medical insurance indications, such as the treatment of soft tissue sarcoma, it is not currently covered by medical insurance, and patients still need to bear the treatment costs out of their own pocket. During the specific implementation process, medical insurance policies in different regions may be slightly different. Some provinces and cities may have incorporated it into a wider range of medication scenarios through local policy pilots. Patients should confirm the most accurate reimbursement policy with the local hospital medical insurance department. In cases of heavy financial burden, some public welfare assistance projects may also provide certain drug exemptions or free cycles.

Overall, pazopanib, as a targeted drug in the medical insurance catalog, provides a good balance between therapeutic effect and economic accessibility for suitable groups, and helps promote the clinical practice of personalized precision treatment.

Reference materials:https://www.votrient.com/